Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn
12/23/2025 05:57 PM • Pelthos Therapeutics Inc. (NYSE American: PTHS) announced the appointment of veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Einhorn brings over four decades of experience in investment banking, capital markets, and C-level finance roles at life science companies. He will serve on the Audit Committee and Compensation Committee. The appointment increases the Pelthos Board to eight directors.
PTHS - The appointment of an experienced finance executive with 40+ years in investment banking and capital markets, combined with 20 years of CFO experience at biotech companies, signals strengthened financial leadership and governance. This is expected to support the company's growth as a newly public, commercially-focused biopharmaceutical company with an FDA-approved product (ZELSUVMI).
Investing.com • Dave Kovaleski